Hu et al. [131] demonstrated through single-cell transcriptional profiling of patient-derived xenografts from EGFR-mutated lung cancer patients that the neuroendocrine transcription factor ASCL1 was upregulated following resistance to osimertinib treatment. The gene discussed is EGFR; the disease is lung carcinoma.